platinum has been researched along with Epithelial Ovarian Cancer in 166 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 72 (43.37) | 24.3611 |
| 2020's | 94 (56.63) | 2.80 |
| Authors | Studies |
|---|---|
| De, A; Deo, AN; Dhadve, AC; Ray, P; Rekhi, B; Thorat, R | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 2 |
| Kajiyama, H; Kikkawa, F; Suzuki, S; Ukai, M; Yokoi, A; Yoshihara, M; Yoshikawa, N | 1 |
| Bondar, O; Patskov, A; Rybin, A; Varabina, A | 1 |
| Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
| Barnicle, A; Bennett, J; Bjurberg, M; Blakeley, C; Cibula, D; Colombo, N; Davidson, R; González-Martín, A; Ledermann, J; Lheureux, S; Lindemann, K; Madry, R; Oaknin, A; Pérez, MJR; Poveda, A; Sikorska, M; Škof, E; Weberpals, J | 1 |
| Abadie-Lacourtoisie, S; Blanc-Fournier, C; Brachet, PE; Briand, M; Clarisse, B; Fabbro, M; Floquet, A; Follana, P; Frenel, JS; Gavoille, C; Giffard, F; Gladieff, L; Joly, F; Just, PA; Kalbacher, E; Leary, A; Leconte, A; Lequesne, J; Lesoin, A; Medioni, J; Poulain, L; Weiswald, LB; You, B | 1 |
| Jimi, T; Kitai, M; Nagao, S; Nakazawa, H; Narita, M; Shibutani, T; Shiozaki, T; Yamaguchi, S; Yano, H | 1 |
| Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Harold, J; Huang, GS; Hui, P; Mauricio, D; Menderes, G; Rao, GG; Ratner, E; Reader, JC; Roque, DM; Santin, AD; Schwartz, PE; Siegel, ER; Silasi, DA; Tymon-Rosario, JR; Zeybek, B | 1 |
| Akilli, H; Aliyeva, K; Altundag, O; Ayhan, A; Kuscu, UE; Rahatli, S | 1 |
| Ikeda, Y; Iyoshi, S; Kajiyama, H; Kato, M; Kikkawa, F; Kitami, K; Koya, Y; Mogi, K; Ohnuma, S; Sugiyama, M; Tamauchi, S; Tazaki, A; Uno, K; Yokoi, A; Yoshihara, M; Yoshikawa, N | 1 |
| Álvarez-Abril, B; Galluzzi, L; García-Martínez, E | 1 |
| Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
| Au-Yeung, G; Freimund, A; Friedlander, M; Krasovitsky, M; Lee, YC; Mileshkin, L; Norris, C; Sivakumaran, T; So, J; Webber, K | 1 |
| Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H | 1 |
| Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Pergialiotis, V; Rodolakis, A; Sotiropoulou, IM; Thomakos, N | 1 |
| Choi, J; Duan, QL; Nesdoly, S; Nicol, CJB; Tarnouskaya, A; Topouza, DG | 1 |
| Bao, H; Feng, Z; Guo, Q; Liu, R; Ma, Y; Ou, Q; Shao, Y; Shen, Y; Wen, H; Wu, X | 1 |
| Li, Y; Liu, C; Sun, L | 1 |
| Clarke, RG; Ferguson, MJ; Hiom, KJ; Nicholson, HA; Sawers, L; Smith, G | 1 |
| Chen, M; Li, Y; Ma, X; Wang, H | 1 |
| Aoki, D; Chiyoda, T; Kobayashi, Y; Kuroda, Y; Nanki, Y; Sakai, K; Saotome, K; Takahashi, M; Yamagami, W; Yoshihama, T; Yoshimura, T | 1 |
| Bi, XH; Huang, X; Huang, Y; Jin, HH; Lan, CY; Li, R; Liu, C; Meng, J; Wang, J; Wang, YF; Xiong, Y; Yang, F; Zhang, L; Zhao, J; Zhao, WH; Zheng, M | 1 |
| Graham, TA; Haughey, MJ; Hoare, JI; Hockings, H; Huang, W; Lockley, M; Maniati, E; McNeish, IA; Mirza, H; Nicolini, F; Saxena, J; Silva, VL; Wood, GE | 1 |
| Fang, F; Lai, T; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sriramkumar, S; Zong, X | 1 |
| Agami, R; Amant, F; Annibali, D; Baiden-Amissah, REM; Berardi, E; Berkers, CR; Carmeliet, P; Davidson, B; De Wispelaere, W; Duarte, JAG; Eelen, G; Fendt, SM; Horlings, HM; Körner, PR; Lambrechts, D; Moens, S; Planque, M; Rizzotto, L; Rossi, M; Sonke, GS; Swinnen, JV; Talebi, A; Van Nyen, T; van Wagensveld, L; Zaal, EA | 1 |
| Chen, X; Cheng, X; Dong, J; Guo, W; Ni, J; Xiao, L; Xu, X; Xue, Q; Zhao, Q | 1 |
| Kristeleit, RS; Moore, KN | 1 |
| Abe, M; Aida, T; Baba, T; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takatori, E; Tatsuki, S; Tomabechi, H | 1 |
| Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA | 1 |
| Bae, BK; Cho, WK; Choi, CH; Kim, TJ; Lee, JW; Lee, YY; Park, W | 1 |
| Colombo, N; Credille, KM; Gao, B; Konstantinopoulos, PA; Lee, JM; Lee, JY; Lin, AB; McNeely, S; Miller, R; Shapira-Frommer, R; Vergote, I; Wang, XA; Young, SR | 1 |
| Bouda, J; Černaj, P; Hlaváč, V; Holý, P; Hruda, M; Mrhalová, M; Rob, L; Souček, P; Václavíková, R | 1 |
| Aghajanian, C; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; Goble, S; Goh, JC; Holloway, RW; Kwan, T; Leary, A; Ledermann, JA; Lin, KK; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
| Chen, M; Jiang, Q; Li, J; Li, T; Luo, X; Sun, Y; Yao, L; Yuan, L | 1 |
| Park, JY; Park, SG; Seo, MD; Sim, YH; Um, YJ | 1 |
| Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Papapanagiotou, A; Pergialiotis, V; Rodolakis, A; Thomakos, N | 1 |
| Jia, Y; Liu, L; Wang, B | 1 |
| Ahmed, N; Goonetilleke, L; Kadife, E; Kannourakis, G; Leung, D; Lokman, NA; Oehler, MK; Price, ZK; Ricciardelli, C; Wang, W | 1 |
| Balmaña, J; Banerjee, S; Borrow, J; Burris, HA; Chen, LM; Domchek, SM; Drew, Y; Glasspool, RM; Goble, S; Kristeleit, RS; Lin, KK; Maloney, L; Oza, AM; Patel, MR; Safra, T; Shapira-Frommer, R | 1 |
| Cheng, X; Fan, F; Fei, W; Gu, J; Qin, J; Shen, S; Shen, T; Wu, X; Zhang, T | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
| Wang, H; Wang, Y; Xia, Y; Zhang, J | 1 |
| Crosbie, EJ; Edmondson, RJ; Faraahi, ZF; Gavrielides, N; Hawarden, A; Jones, DM; McCormick, A; Price, MJ; Roberts, C; Russell, B; Tyagi, S; Waddell, CA; Walker, TDJ; Whalley, B; Woodhouse, LC | 1 |
| Chen, Y; He, H; Li, L; Luo, Z; Pan, Z; Yang, Z; Zhao, B | 1 |
| Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E | 1 |
| Gou, S; Wang, X; Wang, Y | 1 |
| Brennan, DJ; Doran, P; Glennon, K; Jeronimo, C; Lynch, L; Martin, T; Metoudi, M; Moran, B; Perry, AS; Salta, S; Shaw, J; Silva, R; Slattery, K; Treacy, A | 1 |
| Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ | 1 |
| Barth, MC; Häfner, N; Runnebaum, IB; Weigand, W | 1 |
| Cainap, C; Cainap, SS; Havasi, A; Havasi, AT | 1 |
| Albertella, MR; Bani, MR; Decio, A; Dellavedova, G; Formenti, L; Ghilardi, C; Giavazzi, R; Leo, E; Staniszewska, AD; Wilson, J | 1 |
| Su, R; Su, X; Wang, Z; Wu, X; Yang, L | 1 |
| Hu, XQ; Hua, T; Zhang, BY | 1 |
| Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I | 1 |
| Eskander, RN; O'Malley, DM; Richardson, DL | 1 |
| Compadre, AJ; Cooper, I; Fashemi, B; Graham, E; Hagemann, AR; Harrington, SP; Herencia-Ropero, A; Khabele, D; Kotnik, EN; Kuroki, LM; Llop-Guevara, A; Lomonosova, E; McCourt, CK; Mosammaparast, N; Mullen, MM; Mutch, DG; Powell, MA; Serra, V; Sun, L; Thaker, PH; Valentine, MC; van Biljon, LN; Zhao, P | 1 |
| Hamontri, S; Tantitamit, T | 1 |
| Bramhecha, Y; Dorigo, O; Ebrahimizadeh, W; Fiset, S; Ghamande, S; Ghatage, P; Hirsch, HA; Kaliaperumal, V; MacDonald, LD; Oza, AM; Pejovic, T; Provencher, D; Torrey, H; Villella, J | 1 |
| Fujiwara, K; Yoshida, H | 1 |
| Gao, Y | 1 |
| Borgonovo, K; Celotti, A; Ghidini, A; Lorusso, D; Luciani, A; Petrelli, F; Rea, CG; Solinas, C; Villa, A | 1 |
| Elsea, D; Fan, L; Kasle, A; Meng, Y; Mihai, A; Monberg, M; Muston, D | 1 |
| Fujiwara, S | 1 |
| Chen, X; Gao, J; Lin, S; Liu, Y; Yang, X; Zhu, H; Zhu, J; Zou, X | 1 |
| Awazu, Y; Fukuda, T; Ichimura, T; Imai, K; Noda, T; Sumi, T; Tasaka, R; Uchikura, E; Yamauchi, M; Yasui, T | 1 |
| Furukawa, T; Hashimoto, H; Kawasaki, T; Kawazoe, H; Mamishin, K; Nakamura, T; Nishimura, T; Saito, Y; Seto, K; Shimoi, T; Tashiro, R; Terakado, H; Udagawa, R; Yonemori, K; Yonemura, M | 1 |
| Harada, H; Izumi, H; Koi, C; Kurita, T; Murakami, M; Shibahara, M; Yoshino, K | 1 |
| Belin, L; Bultot-Boissier, É; Churruca, C; Cibula, D; D'Hondt, V; de Gregorio, N; Denys, H; Gaba, L; Heitz, F; Heudel, PE; Joly, F; Kocián, R; Kurtz, JE; Largillier, R; Lebreton, C; Leitner, K; Lotz, JP; Martinez García, J; Mouret Reynier, MA; Oaknin, A; Pautier, P; Petru, E; Polterauer, S; Pujade-Lauraine, E; Rodrigues, M; Rosengarten, O; Schmalfeldt, B; Sehouli, J; Selle, F; Vergote, I | 1 |
| Konstantinopoulos, PA; Matulonis, UA | 1 |
| Ahmad, S; Al-Niaimi, AN; Barter, J; Beck, T; Chambers, SK; Coleman, RL; Crafton, SM; Crane, E; Ghamande, S; Graybill, W; Herzog, T; Holloway, RW; Indermaur, MD; John, VS; Landrum, L; Lim, PC; Lucci, JA; McHale, M; Mendivil, AA; Monk, BJ; Moore, KN; Morris, R; O'Malley, DM; Ramez, E; Reid, TJ; Richardson, D; Rose, PG; Scalici, JM; Silasi, DA; Tewari, K; Thaker, P; Wang, EW | 1 |
| Chai, R; Dai, Y; Gao, Y; Kang, Y; Lu, C; Xu, C; Xu, J; Yu, B | 1 |
| Bu, H; Feng, S; Huang, Y; Jin, C; Kong, B; Li, N; Liu, J; Ma, Y; Song, K; Wen, H; Wu, L; Yang, X; Zhang, H | 1 |
| Boekestijn, S; de Bruin, L; de Kok, PM; Kroep, JR; Loof, NM; Meij, P; Roozen, I; Santegoets, SJ; Van der Burg, SH; van der Minne, CE; Verdegaal, EME; Visser, M; Welters, MJP; Westra, IM | 1 |
| Blakeley, C; Davidson, R; Milner, A; Poveda, AM | 1 |
| Amant, FC; Ceelen, WP; De Jaeghere, EA; Denys, HG; Gremonprez, FB; Tummers, PG; Willaert, WC | 1 |
| Färkkilä, A; Hautaniemi, S; Hietanen, S; Hynninen, J; Kozłowska, E; Vallius, T | 1 |
| Baldassarre, G; Citron, F; Mongiat, M; Nicoloso, MS; Pellicani, R; Pivetta, E; Poletto, E; Sonego, M; Sorio, R; Vinciguerra, GLR | 1 |
| Baldassarre, G; Belletti, B; D'Andrea, S; Lorenzon, I; Pellarin, I; Pellizzari, I; Schiappacassi, M; Sonego, M | 1 |
| Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
| Penson, RT | 1 |
| Tomao, F; Tomao, S; Vici, P | 1 |
| Hinchcliff, EM; Meyer, LA; Westin, SN | 1 |
| Brown, EJ; Devins, K; George, E; Greenberg, RA; Hallberg, D; Jagannathan, V; Johnson, N; Kim, H; Kinose, Y; Kumar, S; Ly, K; Medvedev, S; Mills, GB; Scharpf, RB; Schwartz, L; Simpkins, F; Velculescu, VE; Verma, P; Wang, Y; Xu, H; Zhang, R | 1 |
| Jiang, G; Kang, J; Li, W; Liu, L; Owusu, L; Wang, J; Wang, X; Xu, X; Zhang, C; Zhang, L; Zhou, L | 1 |
| Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
| Kang, S; Li, Y; Wu, J; Zhao, J; Zuo, W | 1 |
| Fujiwara, H; Fujiwara, K; Kondo, E; Michimae, H; Motohashi, T; Nishio, S; Nonaka, M; Ohishi, T; Sugiyama, T; Tabata, T; Takano, M; Yabuno, A | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M | 1 |
| Cui, Q; Hu, Y; Liu, H; Ma, D | 1 |
| Abdel-Fatah, T; Alabdullah, ML; Alblihy, A; Algethami, M; Ali, R; Alsaleem, M; Chan, S; Madhusudan, S; Miligy, IM; Mongan, NP; Moseley, P; Narayan, S; Rakha, EA; Toss, MS | 1 |
| Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD | 1 |
| Aghajanian, C; Beltman, J; Brenton, JD; Castro, C; Chen, LM; Coleman, RL; Goble, S; Green, M; Harding, T; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Shapira-Frommer, R; Simmons, AD; Swisher, EM; Tinker, AV; Xiao, JJ | 1 |
| Aghajanian, C; Chambers, SK; Chen, LM; Coleman, RL; Dobrovic, A; Dominy, E; Dorigo, O; Elvin, JA; Ghatage, P; Giordano, H; Goble, S; Harding, T; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Kwan, TT; Leary, A; Lin, DI; Lin, KK; Ma, L; Maloney, L; McNeish, IA; Musafer, A; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Scott, CL; Swisher, EM; Tinker, AV; Vo, LT; Wahner Hendrickson, AE; Welch, S | 1 |
| Harsono, AB; Nisa, AS; Pasaribu, M; Suardi, D; Susanto, H; Trianasari, N; Winarno, GNA; Yuseran, H | 1 |
| Abakumova, TV; Antoneeva, II; Dolgova, DR; Gening, SO; Gening, TP | 1 |
| Elzarkaa, AA; Malik, E; Soliman, AA | 1 |
| Carter, CA; Cottrill, HM; Oronsky, B; Ray, CM; Spira, AI; Trepel, JB | 1 |
| Ebbesson, A; Hartman, L; Hedenfalk, I; Jönsson, JM; Malander, S; Martín de la Fuente, L; Måsbäck, A; Nilbert, M | 1 |
| Chen, Y; Teng, NNH; Westhoff, GL | 1 |
| Baldassarre, G; Belletti, B; Benevol, S; Bomben, R; Dall'Acqua, A; Gattei, V; Lorenzon, I; Pellizzari, I; Pivetta, E; Schiappacassi, M; Sonego, M; Sorio, R; Spessotto, P | 1 |
| Armenia, J; Bagnoli, M; Baldassarre, G; Belletti, B; Benevol, S; Califano, D; Canzonieri, V; Chiappetta, G; D'Andrea, S; Dall'Acqua, A; Giorda, G; Mezzanzanica, D; Militello, L; Pellarin, I; Pellizzari, I; Schiappacassi, M; Sonego, M; Sorio, R | 1 |
| Bañuelos-Ramírez, JL; Cantón-Romero, JC; Carrillo-Ibarra, S; Castellanos-González, JA; Miranda-Díaz, AG; Rodríguez-Carrizalez, AD; Sifuentes-Franco, S | 1 |
| Chung, V; Cristea, M; Diamond, DJ; Ellenhorn, JDI; Eng, M; Frankel, P; Hardwick, NR; Kaltcheva, T; Kilpatrick, J; Kos, F; Leong, L; Morgan, R; Ruel, C; Tinsley, R; Tsai, W; Wilczynski, S | 1 |
| Banerjee, S; Birrer, MJ; Colombo, N; Malek, K; Moore, KN; Oaknin, A; Oza, A; Pautier, P; Vergote, I | 1 |
| Wang, X; Zhang, W; Zhao, D | 1 |
| Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Degasper, C; Fiegl, H; Lax, SF; Marth, C; Shivalingaiah, G; Sprung, S; Tsibulak, I; Wenzel, S; Wieser, V; Zeimet, AG | 1 |
| Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE | 1 |
| Cho, U; Chung, HH; Hwangbo, S; Kim, HS; Kim, JH; Kim, SI; Lee, M; Lee, S; Park, T; Song, M; Song, YS; Suh, DS | 1 |
| Arakawa, A; Chan, MWY; Katsushima, K; Kondo, Y; Lai, HC; Lin, RI; Mase, S; Shinjo, K; Sugiura-Ogasawara, M; Takahashi, S; Totani, H | 1 |
| Bielenberg, DR; Chang, J; Fernandes, D; Gartung, A; Hammock, BD; Huang, S; Hwang, SH; Kieran, MW; Panigrahy, D; Schmidt, BA; Sukhatme, VP; Yang, J; Zurakowski, D | 1 |
| Deng, JL; Li, TL; Liu, YZ; Sun, H; Wan, ZR; Wang, G; Zeng, Y; Zhang, HB; Zhang, R; Zhu, YS | 1 |
| Aglietta, M; Borella, F; Di Renzo, MF; Erriquez, J; Ferrero, A; Genta, S; Ghisoni, E; Giannone, G; Katsaros, D; Maggiorotto, F; Mittica, G; Sarotto, I; Sciarrillo, A; Valabrega, G | 1 |
| Isohashi, F; Kimura, T; Kodama, M; Komura, N; Mabuchi, S; Matsumoto, Y; Ogawa, K; Shimura, K; Tomimatsu, T; Yokoi, E | 1 |
| Nagao, S | 1 |
| Diep, LM; Gajdzik, B; Normann, MC; Oldenburg, J; Rud, E; Solheim, O; Türzer, M | 1 |
| An, X; Feng, Y; Hao, D; He, Y; Jin, X; Li, X; Li, Y; Li, Z; Ma, J; Meng, H; Tang, J; Wang, G; Wang, T; Wang, X; Weng, M; Wu, D; Yang, C; Yang, S; Yang, W; Zhang, L; Zheng, T; Zhu, Y | 1 |
| Amitai Komem, D; Beiner, ME; Ben Ezry, E; Fishman, A; Helpman, L; Kadan, Y; Weitzner, O; Yagur, Y | 1 |
| Aust, S; Cacsire Castillo-Tong, D; Dudek, G; Grimm, C; Horvat, R; Pils, D; Pils, S; Polterauer, S; Reinthaller, A; Schmid, B; Speiser, P | 1 |
| Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K | 1 |
| Benbrook, DM; Hines, L; McCumber, M; Moore, KN; Moxley, KM; Premkumar, P; Queimado, L; Thavathiru, E; Thompson, D; Zuna, RE | 1 |
| Ferrari, F; Gadducci, A; Landoni, F; Peiretti, M; Perrone, F; Sartori, E; Tana, R | 1 |
| Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V | 1 |
| Cui, H; Li, XP; Liu, BJ; Wang, JL; Wang, SJ; Wei, LH; Zhang, G | 1 |
| Hu, P; Kang, S; Li, Y; Qi, BL; Wang, N; Zhou, RM | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Butow, P; Donovan, H; Friedlander, ML; Gillies, K; King, MT; Martyn, J; O'Connell, R; Oza, A; Sjoquist, K; Stockler, M; Voysey, M | 1 |
| Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E | 1 |
| Asano, T; Hirohashi, Y; Kuroda, T; Mariya, T; Mizuuchi, M; Saito, T; Sato, N; Sonoda, T; Torigoe, T; Yasuda, K | 1 |
| Li, L; Shi, L; Wang, Q; Yu, H; Zhang, W | 1 |
| Brachova, P; Button, AM; Carlson, MJ; Dai, D; Devor, EJ; Goodheart, MJ; Leslie, KK; Mott, SL; Mueting, SR; Thiel, KW | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Baldwin, PJ; Brenton, JD; Cooke, SL; Earl, HM; Gale, D; Jimenez-Linan, M; Markowetz, F; Murtaza, M; Newman, S; Ng, CK; Parkinson, CA; Piskorz, AM; Rosenfeld, N; Sala, E; Sayal, K; Schwarz, RF; Temple, J | 1 |
| Kaye, SB; Tan, DS | 1 |
| Chen, DT; Chen, Z; Cheng, JQ; Fulp, WJ; Georgeades, C; Lancaster, JM; Magliocco, A; Permuth-Wey, J; Reid, BM | 1 |
| Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Peng, CW | 1 |
| Anchora, LP; Fagotti, A; Petrillo, M; Scambia, G | 1 |
| Chen, C; Chen, J; Jia, XB; Liu, Y; Wang, HJ; Xu, P; Yang, LY | 1 |
| Almorsy, W; Elshebeiny, M | 1 |
| Feng, Y; Li, B; Li, S; Miao, Y; Yan, Q | 1 |
| Li, L; Wang, Q; Wu, WJ; Zhang, W | 1 |
| Bae, DS; Baek, SY; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES; Shim, M; Sohn, I | 1 |
| Allen, AR; Bell-McGuinn, KM; Brenton, JD; Coleman, RL; Cragun, JM; Floquet, A; Giordano, H; Goble, S; Harding, TC; Harrell, MI; Isaacson, J; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; Mann, E; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Raponi, M; Ray-Coquard, I; Rolfe, L; Scott, CL; Sun, J; Swisher, EM; Tinker, AV; Yelensky, R | 1 |
| Broggini, M; Caiola, E; Ceppi, L; Damia, G; Ganzinelli, M; Garassino, MC; Guffanti, F; Marabese, M; Piva, S; Rulli, E | 1 |
| Aghajanian, CA; Barakat, RR; Bell-McGuinn, KM; Bhatia, J; Gallagher, DJ; Kauff, ND; Konner, JA; Offit, K; Sabbatini, P; Spriggs, DR | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Begent, RH; Boxer, GM; Elmasry, K; Maclean, AB; Morris, RW; Rashid, M; Siddiqui, GK; Wong te Fong, A | 1 |
| Buss, I; Galanski, MS; Garmann, D; Jaehde, U; Kalayda, GV; Keppler, BK; Weber, G | 1 |
| Markman, M | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
| Hai-Yan, S; Na, W; Rong-Miao, Z; Shan, K; Shu-Ying, Y; Yan, L; Yip, BH | 1 |
| Enomoto, T; Kim, A; Naka, T; Ueda, Y | 1 |
| Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W | 1 |
| Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
| Altınbaş, SK; Boran, N; Celik, B; Hızlı, D; Köse, MF; Turan, T; Yılmaz, S | 1 |
| Connor, JP; Felder, M; Kapur, A; Onujiogu, N | 1 |
| Blank, S; Boyd, L; Czok, S; Eberhardt, S; Lee, SJ; Muggia, F; Muller, CY; Pothuri, B; Rutledge, T; Verschraegen, CF | 1 |
| Buyukberber, S; Elkiran, ET; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M; Ozdemir, N; Ulas, A; Unal, O; Urakci, Z; Yaman, S | 1 |
| Conner, M; Dobbin, ZC; Han, HD; Katre, AA; Landen, CN; Lopez-Berestein, G; Nowsheen, S; Shah, MM; Sood, AK; Steg, AD; Yang, ES; Ziebarth, AJ | 1 |
| Biason, P; Campagnutta, E; Giorda, G; Lucia, E; Stopar, A; Talamini, R; Toffoli, G; Visentin, M | 1 |
| Ahn, SE; Bazer, FW; Chung, HH; Han, JY; Jeong, W; Kim, HS; Kim, J; Kim, MA; Kim, MK; Kim, YB; Lim, W; Song, G; Song, YS | 1 |
11 review(s) available for platinum and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature.
Topics: Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Quality of Life; Taxoids | 2022 |
Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum-Paclitaxel Chemotherapy: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models | 2023 |
Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Hyperthermic Intraperitoneal Chemotherapy; Ovarian Neoplasms; Platinum; Prognosis | 2023 |
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2023 |
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Ovarian Neoplasms; Platinum; Polyethylene Glycols | 2023 |
Clinical and translational advances in ovarian cancer therapy.
Topics: Aggression; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum | 2023 |
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2017 |
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids | 2018 |
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome | 2015 |
Therapeutic strategies in epithelial ovarian cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Taxoids | 2012 |
27 trial(s) available for platinum and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Survival Rate | 2022 |
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum | 2022 |
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Topics: Aniline Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thrombocytopenia | 2022 |
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum | 2022 |
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2022 |
Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Immune Checkpoint Inhibitors; Indoles; Ovarian Neoplasms; Platinum; Quinolines | 2022 |
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Topics: BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan | 2023 |
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Treatment Outcome | 2023 |
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life | 2023 |
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Tumor Microenvironment; Viral Vaccines | 2023 |
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols | 2021 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Methylation; DNA-Binding Proteins; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic | 2021 |
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Topics: Adult; Aged; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Maytansine; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate | 2018 |
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide | 2014 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Indoles; International Agencies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2017 |
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids; Treatment Outcome | 2012 |
128 other study(ies) available for platinum and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Integrin alpha6; Mice; Neoplasm Metastasis; Paclitaxel; Platinum; Receptor, IGF Type 1; S100 Calcium-Binding Protein A4; Signal Transduction | 2022 |
Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies; Taxoids | 2022 |
THE QUALITY OF LIFE OF OVARIAN CANCER PATIENTS AS AN INDICATION OF THE EFFECTIVENESS OF PLATINUM-BASED ADJUVANT CHEMOTHERAPY.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Humans; Ovarian Neoplasms; Platinum; Quality of Life | 2021 |
Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2022 |
Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum | 2022 |
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cellular Senescence; Female; Mice; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2022 |
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Retrospective Studies | 2022 |
Novel MicroRNA-Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Regulatory Networks; Humans; MicroRNAs; Ovarian Neoplasms; Platinum; RNA, Messenger | 2022 |
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Topics: BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Platinum; Recombinational DNA Repair | 2022 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carbohydrates; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2022 |
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Drug Resistance; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factors; Humans; Ovarian Neoplasms; Platinum; Recombinational DNA Repair; Replication Protein A; RNA, Small Interfering | 2022 |
The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy.
Topics: Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2022 |
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Microenvironment | 2022 |
Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Topics: Carcinoma, Ovarian Epithelial; Cell Line; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Single-Cell Analysis; Transcriptome | 2022 |
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Serine | 2022 |
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence | 2023 |
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2022 |
Role of salvage radiotherapy for recurrent ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Salvage Therapy | 2023 |
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Exome Sequencing; Female; Humans; Ovarian Neoplasms; Platinum; Precision Medicine | 2022 |
A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.
Topics: Antineoplastic Agents, Immunological; Apoptosis; B7-H1 Antigen; Carcinoma, Ovarian Epithelial; Female; HLA-B44 Antigen; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor | 2022 |
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Immunoconjugates; Immunoglobulin G; Maytansine; Mice; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays | 2022 |
The efficacy and safety of platinum-based chemotherapy for ovarian cancer in pregnancy: A protocol for systematic review and meta-analysis.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Pregnancy; Systematic Reviews as Topic | 2022 |
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Topics: Aldehyde Reductase; Carboplatin; Carcinoma, Ovarian Epithelial; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Ovarian Neoplasms; Platinum; Proteomics; RNA, Messenger; Tumor Microenvironment | 2022 |
High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
Topics: Amino Acid Transport System y+; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Platinum; Prognosis; Retrospective Studies | 2022 |
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
Topics: Carcinoma, Ovarian Epithelial; DNA Damage; Female; Humans; Machine Learning; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia | 2023 |
A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Casein Kinase II; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenomics; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Retrospective Studies; Vinblastine; Vinorelbine | 2023 |
Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Female; Humans; Ovarian Neoplasms; Platinum; Prodrugs | 2023 |
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Topics: Adenocarcinoma; Animals; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Female; Heterografts; Humans; Mice; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Female; Humans; Ovarian Neoplasms; Platinum; RNA; Transcriptome; Tumor Microenvironment | 2023 |
hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Female; Humans; Kaplan-Meier Estimate; MutS Homolog 2 Protein; Ovarian Neoplasms; Platinum | 2023 |
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Rad51 Recombinase | 2023 |
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis | 2023 |
Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.
Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies | 2023 |
Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies | 2023 |
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Effectiveness Analysis; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Quality of Life | 2023 |
Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies | 2023 |
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study.
Topics: BRCA1 Protein; BRCA2 Protein; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Retrospective Studies | 2023 |
Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Ovarian Epithelial; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Prognosis; Ubiquitin-Conjugating Enzymes | 2023 |
RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Topics: Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence; Retrospective Studies; Ribose | 2023 |
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Lymphocytes, Tumor-Infiltrating; Ovarian Neoplasms; Platinum; T-Lymphocytes | 2023 |
Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Heating; Humans; Ovarian Neoplasms; Platinum | 2019 |
Virtual clinical trials identify effective combination therapies in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Computer Simulation; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Models, Theoretical; Ovarian Neoplasms; Platinum; Research Design; Taxoids | 2019 |
TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Staging; Platinum; Proteomics; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Tumor Microenvironment; Up-Regulation | 2019 |
Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Mitosis; Mutation; Ovarian Neoplasms; Ovary; Platinum; Tumor Suppressor Protein p53 | 2019 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Platinum-sensitive ovarian cancer: liminal advances.
Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2020 |
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2020 |
Has dose-dense chemotherapy met an ICONic end?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Quality of Life | 2020 |
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclins; Drug Combinations; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Humans; Mice, Inbred NOD; Mice, SCID; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Rad51 Recombinase; Stem Cells; Xenograft Model Antitumor Assays | 2020 |
Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Phenanthrenes; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; Quinones; Signal Transduction; Transcription, Genetic; Zebrafish | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.
Topics: Carcinoma, Ovarian Epithelial; Case-Control Studies; Female; Genotype; Humans; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Polymorphism, Single Nucleotide; Prognosis | 2020 |
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays | 2021 |
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinolines | 2021 |
Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA Polymerase beta; Female; Humans; Platinum; Transfection | 2021 |
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase | 2021 |
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Topics: Administration, Oral; Aged; Area Under Curve; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2021 |
The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer.
Topics: Adult; Biomarkers, Tumor; Blood Platelets; Carcinoma, Ovarian Epithelial; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indonesia; Lymphocytes; Middle Aged; Neutrophils; Ovarian Neoplasms; Platinum; Prognosis | 2021 |
The Plasticity of Circulating Tumor Cells in Ovarian Cancer During Platinum-containing Chemotherapy.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Epithelial Cell Adhesion Molecule; Humans; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum | 2021 |
Epithelial Ovarian Cancer and Cancer Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum | 2021 |
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carcinoma; Carcinoma, Ovarian Epithelial; Claudin-4; Cohort Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Sweden; Tissue Array Analysis | 2018 |
Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; RNA, Messenger; Thiostrepton | 2017 |
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Phenotype; Platinum; Signal Transduction; Tumor Cells, Cultured | 2017 |
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 6; DNA Damage; Female; Forkhead Box Protein O3; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperazines; Platinum; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antioxidants; Ascites; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Inflammation; Interleukin-6; Isoprostanes; Lipid Peroxides; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Oxidative Stress; Platinum; Tumor Necrosis Factor-alpha | 2017 |
GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Growth Differentiation Factor 15; Humans; Platinum; Prognosis; Retrospective Studies; ROC Curve; Treatment Outcome | 2018 |
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2016 |
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Platinum; Prognosis; Treatment Outcome; Up-Regulation | 2018 |
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Internet; Middle Aged; Nomograms; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; ROC Curve; Survival Rate; Tertiary Care Centers; Treatment Outcome | 2019 |
ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Tumor Suppressor Proteins | 2019 |
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Disease Progression; Epoxide Hydrolases; Female; Inflammation; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, SCID; Ovarian Neoplasms; Platinum; Signal Transduction; Taxoids | 2019 |
Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; China; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Genotype; Haplotypes; Humans; Insulin-Like Growth Factor II; Middle Aged; Platinum; Polymorphism, Single Nucleotide; RNA, Long Noncoding | 2019 |
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies | 2019 |
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Platinum; Radiotherapy; Retrospective Studies; Survival Analysis | 2019 |
[Ⅲ.Surgery for Platinum Sensitive Recurrent Epithelial Ovarian Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2019 |
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents, Immunological; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Nivolumab; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Prospective Studies | 2019 |
miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Comet Assay; DNA Damage; Female; Humans; Immunohistochemistry; In Situ Hybridization; In Vitro Techniques; Mice; Mice, Nude; MicroRNAs; Ovarian Neoplasms; Phosphoric Diester Hydrolases; Platinum | 2019 |
Chemotherapy Toxicity in
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cohort Studies; Female; Humans; Middle Aged; Mutation; Platinum; Retrospective Studies | 2019 |
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Taxoids; Transcription Factors | 2013 |
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome | 2013 |
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Transcription Factors | 2013 |
Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Retrospective Studies; Second-Look Surgery; Treatment Failure; Treatment Outcome | 2013 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome | 2014 |
Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Retrospective Studies | 2013 |
[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Young Adult | 2013 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Platinum; Prognosis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Risk Factors | 2014 |
[Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Repair; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2014 |
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Taxoids; Tumor Suppressor Protein p53 | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
Topics: Aged; Algorithms; Alleles; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phylogeny; Platinum | 2015 |
STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Receptor, Notch1; STAT3 Transcription Factor | 2016 |
Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Databases, Factual; Disease-Free Survival; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Propensity Score | 2016 |
Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
Topics: Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2016 |
[Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance].
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase | 2016 |
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2016 |
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Leukocyte Count; Lymphocytes; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Platelet Count; Platinum; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Treatment Outcome | 2016 |
[Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; China; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proteomics; ROC Curve; Treatment Outcome | 2016 |
Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Cell Count; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nomograms; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Topics: 5' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenomic Variants; Platinum; Polymorphism, Genetic; Survival Analysis; Transcription Factors; Treatment Outcome | 2016 |
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Genetic Association Studies; Humans; INDEL Mutation; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Demography; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2011 |
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; DNA; Drug Resistance, Neoplasm; Endocytosis; Humans; Ligands; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Platinum | 2011 |
Role of chemotherapy in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids | 2011 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
Topics: Adult; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; China; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Genetic; Prognosis; Survival Analysis | 2012 |
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2012 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Heparan Sulfate Proteoglycans; Humans; Ligands; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Protein Binding; Receptors, Tumor Necrosis Factor, Member 6b | 2012 |
Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Etoposide; Female; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Survival; Disease Models, Animal; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Endoglin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Receptors, Cell Surface; RNA Interference | 2013 |
Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Thymidylate Synthase | 2012 |
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Animals; Antigens, Neoplasm; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Transformation, Neoplastic; Chickens; Disease Models, Animal; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Serine Proteinase Inhibitors; Serpins | 2012 |